PXDNL Inhibitors represent a category of chemical compounds that target the enzyme PXDNL, also known as Peroxidasin-like protein. This enzyme is a member of the peroxidase family, which are enzymes responsible for catalyzing the oxidation of a variety of substrates in the presence of hydrogen peroxide. PXDNL, like other peroxidases, contains a heme moiety that allows it to partake in electron transfer reactions, thus facilitating its catalytic activity. As the name suggests, PXDNL shares similarities with the peroxidasin protein, but they each have distinct functions within cells. PXDNL inhibitors are designed to specifically interrupt the activity of this enzyme, without significantly affecting the functions of other peroxidases or related enzymes.
The significance of inhibiting PXDNL arises from its involvement in various biochemical processes within cells. While the exact role of PXDNL in these processes remains an active area of research, it is clear that its enzymatic activity can influence cellular pathways and contribute to certain physiological phenomena. Given its specificity and selectivity, PXDNL inhibitors offer a means to probe the function of this enzyme in various cellular contexts. By blocking the activity of PXDNL, researchers can get a clearer picture of its role in these pathways. The design and synthesis of PXDNL inhibitors involve a deep understanding of the enzyme's active site, its interaction with substrates, and the structural aspects that can be targeted to reduce or eliminate its activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits the tyrosine kinase activity of BCR-ABL, blocking cell signaling in chronic myeloid leukemia. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Targets multiple kinases, including RAF and VEGFR, suppressing angiogenesis and cell proliferation in cancer. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Irreversibly inhibits BTK, a critical enzyme in B-cell signaling, leading to suppression of B-cell malignancies. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Blocks the EGFR tyrosine kinase, disrupting downstream signaling pathways and halting tumor growth in NSCLC. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
Acts as an androgen receptor antagonist, inhibiting androgen binding and signaling in prostate cancer. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
PARP inhibitor that disrupts DNA repair in BRCA-mutated cells. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Specifically inhibits BRAF V600E mutant kinase, impairing MAPK signaling and halting growth in melanoma. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor that suppresses cytokine signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dual Src and BCR-ABL inhibitor, blocking kinase activities and mitigating the progression of CML and other cancers. | ||||||